Table 3

Random-effects pooled results: pregabalin vs. placebo.

Outcome

Treatment effect (θ)

95% CI for θ

U-test

(p-value)

τ2

NNT/NNH

(95% CI)


Efficacy

Reduction in 24-hour pain intensity

-0.901

(-1.234; -0.568)

<0.001

0.147

Response

0.840

(0. 524; 1.155)

<0.001

0.154

5(4;8)

PGI

-1.291

(-1.722; -0.860)

<0.001

0.019


Tolerability

Premature study discontinuation due to:

- Lack of efficacy

0.713

(-1.205; -0.221)

(0.005)

0

- Adverse events

0.926

(0.463; 1.389)

<0.001

0

19 (10; 48)

- Other

-0.209

(-0.721; 0.302)

(0.330)

0

Diarrhoea

-0.660

(-1.734; 0.414)

0.139

0.139

Dizziness

1.900

(1.314; 2.487)

0.028

0.028

Headache

-0.216

(-0.823; 0.392)

0.486

0

Somnolence

2.063

(1.361; 2.764)

<0.001

0


Note:

θ is absolute difference for 24-hour pain intensity.

θ is log-odds ratio for Response, PGI and all tolerability analyses.

τ2 is between-study heterogeneity.

NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for discontinuation due to adverse events.

Quilici et al. BMC Neurology 2009 9:6   doi:10.1186/1471-2377-9-6

Open Data